Featured Research

from universities, journals, and other organizations

Potential Cure For Lymphoma In HIV Patients

Date:
January 14, 2005
Source:
American Society Of Hematology
Summary:
Stem cell transplants have become the standard of care for Patients with relapsed lymphoma, but not for Patients who suffer from both this disease and HIV. A new study showing that this treatment is a viable option for select Patients with HIV-associated lymphoma will be published in the January 15, 2005, issue of Blood, the official journal of the American Society of Hematology.

WASHINGTON (January 7, 2005) – Stem cell transplants have become the standard of care for Patients with relapsed lymphoma, but not for Patients who suffer from both this disease and HIV. A new study showing that this treatment is a viable option for select Patients with HIV-associated lymphoma will be published in the January 15, 2005, issue of Blood, the official journal of the American Society of Hematology.

Because of the immunodeficiency associated with HIV, HIV-positive Patients are more likely to develop lymphoma than HIV-negative individuals, and the treatment for their cancer is far less likely to be successful.

Sonali Smith, M.D., Assistant Professor of Medicine at the University of Chicago notes, "The treatment of malignant lymphomas in HIV-infected individuals remains challenging, due to both the high incidence of refractory disease and the high risk of treatment-related complications. The ability of high dose chemotherapy as demonstrated in this pilot study to effectively treat even refractory disease is highly encouraging and certainly warrants further study."

Researchers from the City of Hope Cancer Center studied 20 Patients (aged 11 to 68) who had HIV and lymphoma, either Hodgkin's or non-Hodgkin's. The selected Patients had undergone previous standard-dose frontline chemotherapy for their lymphoma, but the majority either failed to achieve a complete remission or had relapsed after an initial remission. The median length of study follow-up was approximately two and a half years, with a range of about six months to six years.

All study Patients were to undergo autologous stem cell rescue. In an autologous transplant, stem cells are removed from the patient and frozen for later use. The patient receives high-dose chemotherapy to kill any lymphoma in the body, and the autologous stem cells are then infused back into the patient to repopulate the bone marrow wiped out by the chemotherapy.

Before the transplant, Patients were given one of two conditioning regimens, either high dose chemotherapy alone or in combination with radiation therapy, to destroy the cancerous cells. Most (17 Patients versus three) received the chemotherapy-only option. Radiation therapy was selected for Patients younger than 55 who had poorer prognostic factors: either the cancer had spread to multiple lymph nodes or the patient had bulky disease (indicated by a cancerous mass greater than 5 – 10 cm).

Reversible abnormalities in liver function, a side effect of the intensive treatment, were experienced in a majority of the Patients. One patient, the oldest in the study, developed cardiomyopathy (a weakening of the heart) and kidney failure due to treatment toxicities and died a few weeks after the transplant. Opportunistic infections, such as herpes zoster and cytomegalovirus infection, also occurred in a few Patients after the transplant, but were managed with appropriate therapy.

Throughout the study, all Patients were to receive highly active antiretroviral therapy (HAART) to help reduce these opportunistic infections and improve immunodeficiency, however, only nine Patients were able to tolerate this treatment for the entire study due to side effects such as nausea and inflammation of the mouth lining. The majority of Patients, though, did resume the HAART therapy soon after discharge from the hospital.

Although two Patients died of relapsed lymphoma a few months after transplant, 17 of the 20 Patients (85 percent) are currently alive and in remission. In addition, the underlying HIV infection did not worsen as a result of the transplant and associated treatments.

"The results of this study are significant because, despite the use of effective antiviral drugs such as HAART, lymphoma is still a major cause of suffering and death in HIV-infected individuals. It's important to know that stem cell transplant is an available and highly successful treatment option for these Patients," said Amrita Krishnan, M.D., a staff physician at the City of Hope Cancer Center and lead author of the study.

###

This work was supported in part by United States Public Health Service Grants CA30206, CA33572, AI38592, and MO1 RR-43 from the General Clinical Research Center branch of the National Center for Research Resources, National Institutes of Health. Amrita Krishnan, M.D., was the recipient of a Lymphoma Research Foundation of America Fellowship Award. Co-author Arturo Molina, M.D., was the recipient of an American Cancer Society Clinical Oncology Career Development Award.

The American Society of Hematology (http://www.hematology.org) is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology.

Blood, the official journal of the American Society of Hematology, is the most cited peer-reviewed publication in the field. Blood is issued to Society members and other subscribers twice per month, available in print and online at http://www.bloodjournal.org.


Story Source:

The above story is based on materials provided by American Society Of Hematology. Note: Materials may be edited for content and length.


Cite This Page:

American Society Of Hematology. "Potential Cure For Lymphoma In HIV Patients." ScienceDaily. ScienceDaily, 14 January 2005. <www.sciencedaily.com/releases/2005/01/050110115101.htm>.
American Society Of Hematology. (2005, January 14). Potential Cure For Lymphoma In HIV Patients. ScienceDaily. Retrieved September 21, 2014 from www.sciencedaily.com/releases/2005/01/050110115101.htm
American Society Of Hematology. "Potential Cure For Lymphoma In HIV Patients." ScienceDaily. www.sciencedaily.com/releases/2005/01/050110115101.htm (accessed September 21, 2014).

Share This



More Health & Medicine News

Sunday, September 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com
Sierra Leone's Nationwide Ebola Curfew Underway

Sierra Leone's Nationwide Ebola Curfew Underway

Newsy (Sep. 20, 2014) Sierra Leone is locked down as aid workers and volunteers look for new cases of Ebola. Video provided by Newsy
Powered by NewsLook.com
Changes Found In Brain After One Dose Of Antidepressants

Changes Found In Brain After One Dose Of Antidepressants

Newsy (Sep. 19, 2014) A study suggest antidepressants can kick in much sooner than previously thought. Video provided by Newsy
Powered by NewsLook.com
Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins